Effexor

(venlafaxine)

ApprovedSmall molecule

Venlafaxine is used to treat depression, anxiety disorders, and panic disorder by helping to balance chemicals in the brain that affect mood and emotions.[2] Effexor is currently approved and in use across 20 indications[4].[1]

Effexor is one of 471 small molecule programs targeting Hot flashes. It is currently in Approved.

Indications

111

Total Trials

Active Trials

470

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Hot FlashesCompleted

Major Depressive DisorderCompleted

Memory ImpairmentActive, not recruiting

MigraineActive, not recruiting

Depressive DisorderActive, not recruiting

DyspepsiaActive, not recruiting

Morbid ObesityActive, not recruiting

Acute Kidney InjuryActive, not recruiting

Bipolar DisorderActive, not recruiting

Sleep DisorderActive, not recruiting

Hot FlashesPhase 3

Completed

Major Depressive DisorderApproved

Completed

Memory ImpairmentApproved

Active, not recruiting

MigraineApproved

Active, not recruiting

Depressive DisorderApproved

Active, not recruiting

DyspepsiaPreclinical

Active, not recruiting

Morbid ObesityPreclinical

Active, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

Bipolar DisorderPreclinical

Active, not recruiting

Sleep DisorderPreclinical

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

143 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Effexor

WWyeth-Lederle Vaccines

Approved

1 2

Toradol

Roche

Preclinical

1 3

Cataflam

Bayer Aspirin

Enbrel

2 6

Glucophage

EMD Serono

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Bariatric Surgery

NCT03532477

Post-ApprovalRecruiting

Pain

NCT06803485

Q2 2028

Phase 3Recruiting

Major Depressive Disorder

NCT05603104

Phase 3Recruiting

First-Line Treatment

NCT05973786

Q3 2028

Recruiting

Lactating Women on Select DOI

NCT03511118

Q4 2028

Phase 2Recruiting

Obsessive-Compulsive Disorder

NCT04539951

Clinical

Trials by Indication[1]

Depression8 trials

Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1

Completed·NNew York State Psychiatric Institute·Phase 2·NCT00131456·123 enrolled

Optimizing Electroconvulsive Therapy for Depression

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00045916·340 enrolled

Treatments for Depression: Drug Versus Psychotherapy

Completed·UUniversity of Pennsylvania·Phase 3·NCT00043550·156 enrolled

Show 5 more trials

Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression

Completed·—··NCT03126188·105 enrolled

A Study Of New Medicine (GSK 372475) For The Treatment Of Depression

Completed· GSK logo

GSK·Phase 2·NCT00448058·396 enrolled

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177671·220 enrolled

Duloxetine vs. Active Comparator in the Treatment of Patients With Depression

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00071695·320 enrolled

Duloxetine vs. Active Comparator for the Treatment of Depression

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00067912·480 enrolled

Major Depressive Disorder8 trials

Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks

Completed·UUniversity Hospital, Grenoble·Phase 3·NCT01557712·25 enrolled

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT00435279·678 enrolled

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting·—·Phase 3·NCT05603104·1,254 enrolled

Show 5 more trials

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·Phase 4·NCT01764867·1,080 enrolled

Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)

Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 4·NCT02051413·67 enrolled

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT01571453·437 enrolled

Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder

Terminated· Lundbeck logo

Lundbeck·Phase 2·NCT00766870·35 enrolled

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Completed· AstraZeneca logo